Abstract Nonalcoholic fatty liver disease (NAFLD) is a complex liver disease with worldwide prevalence. Its development involves a myriad of factors, including genetic susceptibility and environmental insults. In this review, we summarize new findings about current genome-wide association studies on NAFLD. In addition, we used a strategy of functional enrichment analysis to integrate all the newly discovered loci into common biological pathways and to explore their role in the pathogenesis of NAFLD. Controversies on the application of genetic testing to predict disease severity are discussed and specifically the role of rs738409 in clinical decision making. Finally, we highlighted significant trends and developments in epigenetic changes and microRNAs associated with disease progression.
Introduction
Nonalcoholic fatty liver disease (NAFLD) is a liver disease that is prevalent worldwide. It develops from a complex process that involves a myriad of factors, including individual genetic susceptibility and particular environmental insults. Until a few years ago, our knowledge about the genetic components of NAFLD and nonalcoholic steatohepatitis (NASH), the more severe clinical form of NAFLD, was based on results from candidate gene association studies that identified several loci associated with disease susceptibility and progression [1] . Although all of these studies were inspired by biological plausibility, only a few of them were replicated. A remarkable breakthrough in our understanding of the genetic susceptibility to NAFLD was however provided by findings from the first genome-wide association (GWAS) study on NAFLD done by the Dallas Heart Study in 2008 [2] .
Environmental factors, such as physical activity [3, 4] and diet intervention [4] [5] [6] , play an important role in the development of NAFLD. Interestingly, evidence from human studies have provided clues about how gene-environment interactions modulated by epigenetic mechanisms impact not only on the pathogenesis of NAFLD but also the modulation of metabolic syndrome (MetSyn)-related phenotypes, including insulin resistance (IR) [7••, 8] .
Finally, although by definition NAFLD is characterized by abnormal liver fat accumulation in the absence of significant alcohol consumption and other causes of secondary hepatic steatosis [9] , evidence from clinico-epidemiologic [10] , histologic studies [11] , and even in silico systems biology of the disease [12] suggests that NAFLD and alcoholic liver disease (ALD) share many disease determinants, including the same underlying genetic risk [13] .
Hence, this review summarizes new findings about GWAS on NAFLD and significant trends and developments on the epigenetic component of the disease. In addition, controversies about disease pathogenesis and management derived from recent discoveries on gene variants are also discussed.
GWAS on NAFLD and Our Knowledge About Disease Pathogenesis
The first GWAS on NAFLD was a genome-wide survey of non-synonymous sequence variations encompassing 9229 single nucleotide polymorphisms (SNPs) in a multiethnic population-based study [2] . The authors uncovered a significant association of the patatin-like phospholipase domain containing 3 (PNPLA3, also known as adiponutrin) rs738409 C/G variant, encoding an amino acid substitution (I148M) with liver triglyceride accumulation [2] . This association remained significant even after adjusting for common metabolic confounders such as obesity, diabetes status and related risk factors of disease, such as ethanol use.
Soon thereafter, this finding was replicated, and the PNPLA3-148 M allele was significantly associated with disease severity [14] . rs738409 is widely acknowledged as the "NASH gene" because the association is largely replicated around the world not only in adults but also in children [15] . Of note, the risk effect of rs738409 on developing fatty liver is perhaps one of the strongest ever worldwide-replicated effect for a common variant modifying the genetic susceptibility to a complex disease (5.3 % of the total variance) [14] . In addition, homozygous GG carriers have a 3.24-fold greater risk of higher necroinflammatory scores and a 3.2-fold greater risk of developing fibrosis when compared with homozygous CC [15] . Interestingly, the genetic models do not seem to be similar for liver fat and disease severity, and, at least for liver fat deposition, the effect of the variant seems to be greater in women than in men [15] .
The use of a GWAS strategy in the search for the genetic basis of NAFLD was followed by other reports that included different populations, study designs, sample sizes, and approaches for the characterization of the main liver phenotype. For example, studies have been undertaken of female adults with NAFLD diagnosed by liver biopsy [16] , of the heritability of hepatic steatosis at the population level with computed tomography (CT) [17] , a combined approach of CT and alanine-aminotransferase (ALT) levels as a surrogate of disease severity [18] , and exploration of the genetic risk in Asiandescent patients [19, 20] .
It is important to highlight that the coverage of SNPs by the above-mentioned GWA studies was not uniform in terms of the explored variants. In addition, it varied from a GWAS analysis of 12,138 non-synonymous sequence variations from dbSNP and the Perlegen SNP database [2] to commercial platforms, such as HumanCNV370-Quadv3 BeadChip (coverage: 373,397 SNPs) [16] or Illumina Human 610-Quad BeadChip (coverage: 484,751 SNPs), meta-analysis and GWAS association data of large consortiums that used the Affymetrix 6.0 or Illumina platform [17] , and imputed SNPs [18] .
Finally, the GWAS strategy has also been used to explore the genetic locus that influences liver enzyme levels in the population, including ALT [21, 22] . A summary of the latest GWAS on NAFLD and ALT levels is depicted in Fig. 1 . Surprisingly, the most significant findings are on chromosome 22 at PNPLA3 loci, and rs738409 is still the most consistently replicated variant associated with fatty liver, disease severity, and associated traits, such as ALT levels. Likewise, rs738409 is consistently associated with NAFLD across different populations [15, 23, 24] .
Hence, a number of questions emerge from these results. For instance, we may wonder whether these findings are an indication that the genetic risk of NAFLD is so far explained by a single common variant with a minor allele risk frequency of~30 %. If so, do the findings fit the concept that NAFLD, like many other common complex diseases, including type 2 diabetes or obesity, is a complex trait influenced by the effect of multiple gene variants? The answer is a definitive yes and that, although the effect size of the variant is one of the biggest ever observed for a common SNP, a significant proportion of the heredity of the trait is missing. The question remains whether carriers should be closely monitored for serious complications of NASH, such as hepatocellular carcinoma [25] .
Alternatively, we might wonder whether or not rare variants have a place in the genetic predisposition to NAFLD. In this sense, NAFLD, at least up to now, differs from other complex diseases in that no truly monogenic forms (patients with rare genetic variants with penetrance high enough to explain the phenotype) have been described. Unfortunately, there are no data about variants with a minor allele frequency of less than 1 % influencing the susceptibility to NAFLD.
However, a recent study that did whole-exome sequencing of five loci associated with NAFLD on a small sample of patients with extreme obesity (BMI >50) and NAFLD-related cirrhosis showed that one of four patients was compound heterozygous for putatively rare damaging mutations in PNPLA3 [26] . Conversely, Cefalu et al. used exome sequencing to discover a novel nonsense mutation in exon 26 of APOB (p.K2240X) responsible for a low cholesterol and fatty liver in a large kindred with familial hypobetalipoproteinemia in which fatty liver is a common feature. This mutation may also be responsible for cirrhosis and liver cancer in this family [27] .
Another important question that remains under investigation is the unknown role of non-PNPLA3-NAFLD-GWASassociated variants in the modulation of disease. One may wonder whether or not they have a biological connection either with each other or with the disease. To answer this question, we used a strategy for functional enrichment analysis based on an algorithm that weighs among other options, gene ontology and the underlying biological process to predict in silico a network among the input genes/proteins (GeneMANIA) [28] . This strategy not only predicts information about co-expression, physical protein and genetic interaction, co-localization, and common pathways among input genes/proteins, but also extends the list to functionally similar genes. The analysis shows that seven new predicted genes/protein, including GYS1 (glycogen synthase 1, muscle), GYS2 (glycogen synthase 2, liver), PHKG1 (phosphorylase kinase gamma 1, muscle), PHKG2 (phosphorylase kinase gamma 2, testis), PHKB (phosphorylase kinase beta), PHKA1 (phosphorylase kinase alpha 1, muscle), and PHKA2 (phosphorylase kinase alpha 2, liver) were significantly associated with biological pathways that included the glycogen and glucan metabolic process (a series of chemical reactions involving glucans, polysaccharides consisting only of glucose residues) and polysaccharide and carbohydrate metabolism ( Table 1) . Table 1 provides detailed information about the interrelated biological functions of the NAFLD-GWAS-associated genes. Surprisingly, PNPLA3 does not show either genetic interaction, biological pathways, or a shared protein domain with any of the input or newly predicted genes. Indeed, the family of patatin-like phospholipases consists of glycoproteins that account for up to 40 % of the total soluble protein in potato tubers [29] . Remarkably, besides the phospholipase activity, patatin is an inducible storage protein. The protein encoded by the PNPLA3 gene is an intracellular multifunctional enzyme that has both triacylglycerol lipase and acylglycerol Oacyltransferase activities [30] and shares domain and protein function with other members of the PNPLA family [31] . The protein has the serine lipase consensus motif GXSXG/A [32] , which might have a role in the modulation of PNPLA3 by posttranslational modifications, including protein phosphorylation. In fact, PNPLA3 has many sites, including 21 Ser, 5 Thr, and 2 Tyr, with a high potential to be phosphorylated [33] , being 134S close to the polymorphic I148M site. However, in spite of previous efforts, the functional meaning of the I148M variation remains to be established [31, [34] [35] [36] [37] [38] .
GWAS on NAFLD and Translation of the Genomic Information into Clinical Practice
Whether or not the significant association between rs738409 and NAFLD and disease progression might be translated into clinical practice in terms of personalized medicine remains an open question. In such a scenario, it should be possible to make an individual risk assessment, and then the physician might be able to tailor a medical intervention (liver biopsy or disease therapy) based on the PNPLA3 profile of the patient.
Unfortunately, despite the enormous enthusiasm for rs738409, current evidence shows that the role of the variant in predicting disease risk is not significantly improved compared with existing biomarkers of disease severity. For example, Kotronen and coworkers evaluated the performance of this SNP in predicting NAFLD by combining routine clinical and laboratory data and the rs738409 genotypes and observed a sensitivity of 86 % and a specificity of 71 % in the estimation of increased liver fat content [39] . Surprisingly, the addition of genetic information to the score improved the accuracy of the prediction by <1 %. Likewise, Francque et al. explored a set of routine and non-routine parameters, including ultrasound and genetic testing to predict the development of NASH in overweight or obese patients [40] . The authors observed that increased levels of ALT, fasting levels of C-peptide, and ultrasound steatosis scores had area under the receiver operating curve (AUROC) values of 0.854 and 0.823 for NASH development in the design and validation cohort, respectively [40] . In addition, the authors observed that although the levels of cytokeratine 18 and rs738409 correlated with the development of NASH, these did not add value to disease risk prediction [40] . Similarly, a recent study in a cohort of patients with medically complicated obesity showed that the probability of developing NASH was best predicted by a combination of four risk factors (the rs738409 G allele, CK-18 >145 IU/l, glucose >100 mg/dl, and C-reactive protein (CRP) >0.8 mg/ dl): 82 % probability in the presence of all four risk factors versus 9 % in their absence) [41] .
In conclusion, the incorporation of genetic tests in clinical practice is not that much more promising than the consideration of traditional and non canonical risk factors, which, when combined properly, have good predictive power [42, 43] . By contrast, following their observation that carriers of the GG genotype showed a twice higher independent risk for mortality, Hassan et al. reported that rs738409 may help predict poor survival and outcome of hepatocellular carcinoma [44] . Nevertheless, the importance of rs738409 in risk prediction remains unclear because, in the same cohort [44] , other significant risk factors, including viral infection (HCV and HBV) and diabetes mellitus, also had significant predictive value. Indeed, because of the small effect associated with common variants, similarly to other complex diseases, genetic markers are still poor predictors [38] .
Hence, the role of rs738409 in clinical decision making remains uncertain because there are no data to support that interventions should be restricted to carriers of the risk allele. In addition, clinicians who consider having their patients genotyped for the PNPLA3 variant should carefully consider what type of information or recommendation could be returned to their patients, or the parents in the case of a pediatric population, because we do not yet have evidence as to whether patients carrying the risk variant will have a poor prognosis or even poor treatment response to any therapy. The bottom line is that to have an impact on predictive power, any variant should confer an odds ratio or risk of having the Prediction of gene-associated functions was done by using the bioinformatic resource GenMANIA [28] . The input genes are illustrated in Fig. 1 disease of >10-200. Even in the best scenario and after combining many variants, such odds ratio may be reached. However, this would benefit a very small proportion of patients, at least in the absence of epistasis (a genetic interaction among the variants), a phenomenon that remains largely unexplored.
Epigenetic Changes, the Pathogenesis of NAFLD and MetSyn, and Potential Reversion of the Phenotype by Therapeutic Intervention
Epigenetic modifications have emerged as important mechanisms that modulate the pathogenesis of common diseases, including NAFLD, and present a potential explanation for the missing heredity. The main reason for this observation is that epigenetic changes are able to operate across the entire genome by regulating gene transcription and chromosome organization without affecting, by definition, the DNA sequence itself. More interestingly, epigenetic mechanisms are both highly regulated by environmental stimuli, including nutritional status, and highly dynamic. One of the most common epigenetic modifications is DNA methylation, which occurs preferentially but not exclusively in the cytosine of the dinucleotide CpG. In normal conditions, the notable exceptions are the CpG-rich islands (regions typically 300-3000 bp in length with a high percentage content of CpG and C/G) present in the 5'-untranslated regions (5' UTR or promoters) of some genes. Nevertheless, epigenetic changes are not restricted to DNA methylation but also involve histone posttranslational modifications [45] . Therefore, although a comprehensive discussion of this issue is outside the scope of this review, it should be mentioned that many actors play a role in the epigenetic landscape; for example, DNA methyl transferases (DNMTs) and demethylases (TET and jumonji-domain protein families), and histone acetylases (HAT), deacetylases (HDAC), methylases, and demethylases [46] .
Although epigenetics has attracted the genomic world in the last couple of years, the research agenda around NAFLD and epigenetics is very short, and our knowledge about epigenetic changes in human NAFLD is restricted to four studies. Our group showed the effect of epigenetic changes occurring in the fatty liver on the modulation of IR [8] . Further, we observed that the methylation status of the peroxisome proliferator-activated receptor gamma coactivator 1α (PPARGC1A) promoter is significantly associated with plasma fasting insulin levels and the homeostasis model assessment of IR (HOMA-IR) [8] . In addition, the methylation status of the PPARGC1A promoter was inversely correlated with the liver expression of the mRNA, suggesting that methylation of the explored CpG sites in the gene promoter efficiently repressed its transcriptional activity [8] . We also observed a complex interaction between the transcriptional activity of PPARGC1A and liver mitochondrial DNA copy number, which also had a direct impact on IR [8] . In our population, we showed that mitochondrial biogenesis was reduced in the liver of NAFLD patients and was associated with the peripheral IR and PPARGC1A promoter methylation status. A similar finding was observed in an experimental model of NAFLD [47] . It is worth noting that PPARGC1A is a master regulator of mitochondrial biogenesis and cell metabolism [48, 49] . Interestingly, many of these results were also observed in leukocyte DNA from adolescents [50] and umbilical cord DNA from small and large for gestational age in comparison with normal for gestational age newborns [51, 52] . Both extremes of fetal growth have been associated with MetSyn later in life, probably through epigenetic reprogramming of developmental and metabolism pathways [53] .
An interesting study explored the pre-and post-bariatric changes in the methylation profile of nine genes coding for enzymes that regulate intermediate metabolism and insulin signaling in the liver of morbidly obese patients with NAFLD [54•] . The most remarkable finding of this study is that NAFLD-associated methylation changes were partially reversible by therapeutic intervention; for instance, the gene encoding protein-tyrosine phosphatase epsilon (PTPRE) showed both differential expression and differential methylation before and after bariatric surgery [54•] . Moreover, the authors observed that the insulin-like growth factor binding protein 2 (IGFBP2) locus was hypermethylated and its mRNA downregulated in NASH [54•].
Murphy and colleagues, who recently did global methylation profiling of liver samples of NAFLD patients at different stages of disease severity by using the Illumina HumanMethylation450 BeadChip platform, observed that patients with advanced NAFLD had a signature of differentially methylated CpG sites that allow discrimination between advanced versus mild disease [55•] . Indeed, the authors showed that advanced NAFLD has a relative hypomethylation state (11 % of 52,830 CpG sites) compared with mild NAFLD, specifically in genes associated with tissue repair; for instance, FGFR2 (a fibroblast growth factor receptor family member), genes of the collagen (COL1A1, COL1A2, COL4A1, and COL4A2) and laminin families, and many chemokines [55•] . Of note, genes involved in pathways that generate methyl groups, including methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) were significantly hypomethylated in advanced NAFLD [55•] . Finally, we recently described a novel disease mechanism associated with NAFLD progression that involves epigenetic changes of mitochondrial DNA (mtDNA) [7••] . In our study, we explored for the first time the status of cytosine methylation of liver mtDNA in target regions of the mtDNA genome. We observed that the methylation levels of NADH dehydrogenase 6 (MT-ND6), the gene that encodes for a key enzyme of complex 1 of the oxidative phosphorylation chain, were higher in the liver of NASH patients and that there was a clear decrease in the protein level and changes in mitochondrial morphology, suggesting that the methylation status of this mitochondrial gene plays a role in the phenotypic switching from SS to NASH [7••] . To contrast with the hypothesis that epigenetic modifications might be reversible by intervention, we also explored whether the observed changes were associated with interventional programs. We observed that physical activity modulates the methylation status of MT-ND6 [7••] .
In summary, epigenetics emerged as an interesting target of therapeutic intervention in chronic human diseases because it offers a unique framework of reversible mechanisms that modulate the cellular transcriptional machinery. For example, we observed that rs41318021 in the 3′-UTR of the human L-arginine transporter SLC7A1 was significantly associated with arterial blood pressure in patients with NAFLD, suggesting a promising role for miRNAs in the epigenetic regulation of disease-associated traits in NAFLD patients [56] . Table 2 summarizes the results of human studies that have explored the expression of miRNAs either in circulation or in liver tissue. As expected, miRNA-122, the most abundant miRNA in the liver, is the most largely replicated miRNA deregulated in NAFLD; however, the mechanisms by which this miRNA operates in the modulation of the disease severity remain unclear. Evidence from in vitro silencing of miRNA-122 shows a time-regulated increase/decrease in the mRNA levels of lipogeneic genes, suggesting that miR-122 may operate by posttranslational regulation of mRNA maturation [61] .
The exploration of enriched disease-associated pathways among miRNAs significantly deregulated in NAFLD by the bioinformatic resource TAM (a tool for annotation of human miRNAs; http://202.38.126.151/hmdd/tools/tam.html/) shows that miRNAs 122, 19a.b, 34a, and 21 are involved in the regulation of angiogenesis (p value<0.00004, Bonferoni p <0.014).
Finally, we used the resource DIANA-miRPath v2.1 (http://diana.imis.athena-innovation.gr/DianaTools/) to identify common disease pathways associated with the miRNAs mentioned in Table 2 . Interestingly, we found a significantly predicted pathway associated with cancer (empirical p value = 3.0 E -7 , false discovery correction) involving four miRNAs (hsa-miR-122-5p, hsa-miR-192-5p, hsa-miR-375, and hsa-miR-146b-5p) and targeting 46 genes, which might explain the role of the discovered miRNAs miR-122 level was significantly decreased in subjects with NASH. miR-34a and miR-146b levels were significantly increased in subjects with NASH Pirola et al. 2013 [60] Case-control, patients with NAFLD proven by liver biopsy N=65 miR-122 level was 10-fold decreased in subjects with NASH.
associated with NAFLD in the progression of the disease and hepatocarcinogenesis. Interestingly, many of the predicted targets of these miRNAs have been shown to be dysregulated in NASH versus simple steatosis [62] . . & Epigenetic changes are promising molecular mechanisms for explaining disease pathogenesis. The dynamic nature of epigenetic modifications is an attractive target for therapeutic intervention because of the potential reversibility of the liver changes observed in NAFLD after physical activity or bariatric surgery and even after the administration of existing drugs or natural compounds. Mitochondrial epigenetics has emerged as an interesting mechanism for explaining disease transition from simple steatosis to NASH. & Noncoding miRNAs are deregulated in the circulation and in the liver of NAFLD patients and might explain the predisposition to liver cancer.
Conclusions

